NCT01841723 2026-03-18
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT05828082 2026-03-18
Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07112053 2026-03-09
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT04275661 2026-02-04
Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery
Assiut University
Phase 2 Completed
NCT06411795 2026-02-03
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT06635980 2025-12-12
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Mayo Clinic
Phase 2 Recruiting
NCT04329065 2025-11-06
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
University of Washington
Phase 2 Recruiting
NCT07016399 2025-10-30
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT05919108 2025-09-09
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting